INDEX TO VOLUME 165

Author Index

Abbott, S., 740
Abrams, J. S., 506
Abu Kwaik, Y., S195
Achtman, M., 53
Adderson, E. E., S57
Agis, F., 369
Agoki, E., 949
Ahlm, C., 934
Ahmed, F., 161
Ahmed, M. A., S201
Ahrne, H., 994
Aiyappa, A., 585
Ajello, L., 175
Alary, M., 565
Alberti, A., 181
Albus, A., 749
Alexander, L. K., 134
Alexandrescu, C., S115
Al-Ghassani, A. A. K., 444
Alley, E. S., 964
Allred, D. P., 175
Alm, B., S38
Almeido-Hill, J., S129, S144
Alpert, G., 494
Al-Waili, N. S. D., 1170
Amako, K., 183
Ampel, N. M., 710
Anaissie, E. J., 1155
Anders, J., S114
Andersen, L. I., 389
Anderson, E. L., 727
Anderson, E. C., 1069
Anderson, L. J., 456
Anderson, P., S110, S160
Anderson, R., 456
Anderson, S. K., 749
Andersson, B., 994, S38
Andersson, J., 994
Andrac, L., 778
Aniansson, G., S38
Antonelli, G., 593
Anttila, M., S36
Apicella, M. A., S195, S198, S203
Appleyard, M., 389
Arana, B. A., 518, 528
Arana, F. E., 528
Araujo, F. G., 788
Arcia, J., 93
Arencibia-Mireles, O., 644
Argani, I., 155
Argyle, J. C., 644
Armbruster, C., 783
Armstrong, D., 960
Artini, M., 180
Arvin, A. M., 119, 852
Asher, L. V. S., 835
Ashley, R., 813
Atkinson, W. L., 920
Aujard, Y., 147, 569
Axelrod, H. R., 757
Bach, J. F., 364
Badaró, R., 535, 1094
Baddour, L. M., 749
Baden, H. P., 968
Badolato, M. C., 180
Bailey, C. C., 886
Bailey, T. C., 548
Bakaletz, L. O., S196, S201
Baker, P. J., S44
Baker-Zander, S. A., 69, 396
Baldwin, G., 494
Balis, F. M., 99
Balsano, C., 180
Band, H., 506
Banks, R., 886
Barbaree, J. M., 736
Barenkamp, S. J., S181
Baric, R. S., 134
Barnes, P. F., 506
Barral, A., 535, 1094
Barral-Netto, M., 535
Barre-Sinoussi, F., 364
Barrett, T. J., 979
Barthold, S. W., 471
Bartlett, J. G., 913
Bartlett, M. S., 764
Bartok, A. E., 93
Bary, M., 364
Baudry, B., 141
Bauer, D., S74
Baughn, R., 553
Baur, A., 419
Baylor, N. W., 433
Beati, L., 1167
Beddows, S., 256
Beier, P. L., 819
Bejarano, G. C., 710
Bektesh, S., S106
Belshe, R. B., 727
Benach, J. L., 658
Benhamou, J. P., 595, 723, 1164
Benson, A., 987
Benson, R. F., 736
Berggren, T., 299
Bergmann, K. F., 929
Berland, R., 1127
Berman, J. D., 528, 764, 968
Bermudez, L. E., 75
Bernard, E., 787
Bernuau, J., 595
Berzofsky, J. A., 1012
Betts, J., 865
Beuvery, E. C., S152
Bienzle, U., 501
Bijlmer, H. A., S29
Bingen, E., 147, 569
Binn, L. N., 835
Bitran, J. D., 793
Bittker, S., 155
Bjermer, L., 934
Black, S. B., S139
Blanchard, D. K., 702
Blaney, S. M., 99
Blaser, J., 281
Blattner, W. A., 268, 920
Blevins, A., 960
Blitstein-Willinger, E., 501
Block, C., 785
Blok, W. L., 898
Blot, P., 147
Bodey, G. P., 1155
Boersma, W. G., 397
Bohnsack, J. F., 315
Boissinot, C., 147
Bolard, J., 337
Bollinger, R. C., Jr., 913
Bonner, D. P., 732
Bonnez, W., 376
Boone, T., 689
Bosley, G., S34
Bothamley, G. H., 598
Boucher, C. A. B., 105
Bourgeault, J., 908
Boutonnier, A., 1064
Bowden, R. A., 972
Boyer, K. M., 1049
Boyer, N., 723
Bozzette, S. A., 93
Braddick, M., 262
Bradley, D. W., 835, 1001
Brahimi, N., 147, 569
Brandtzaeg, P., S167
Brasini, A., 779
Brazilian Purpuric Fever Study Group, S16
Brechot, C., 720
Breider, M. A., 651
Breiman, R. F., 736
Briles, D. E., 671
Brockhaus, W., 419
Brodeur, B., S86
Brodeur, B. R., S162
Brogan, S., 444
Bronson, R. T., 846
Broome, C. V., S34
Brotman, B., 438
Brouwers, P., 99
Brown, J. M., 175
Bruce, A. W., 1142
Brunham, R. C., 1076
Bryant, R. E., 676
Bucher, D., 155
Burchett, S. K., 813
Burke, D. S., 185
Burke, J. P., 14
Burns, J., 456
Burroughs, M., S82
Butler, J., 716
Butler, K. M., 99
Butler, P. D., S90
Buurman, W. A., 898
Byrd, L. T., 1082
Byrd, R. G., 638
Cabellos, C., S82
Cadman, E. C., 781
Cal, S. X., 1082
Callow, D., 256
Callow, M. G., S75
Campbell, C. H., Jr., 251
Candler, E., Jr., 623
Canessa, A., 1168
Cannon, R. O., 251, 920, 1124
Cao, C. X., 322
Carbon, C., 337
Carl, M., 1145
Carl, M., 581, 1001
Carlson, E., 1056
Carlsson, M., 994
Carman, W. F., 127
Carrigan, D. R., 925
Carroll, W. L., S57
Carvalho, E. M., 535, 1094
Casadevall, A., 1086
Castellazzo, A., S198
Cate, T., 553
Cates, K. L., 942, S70
Caudill, J. D., 835
Caugant, D. A., 46
CDC Meningitis Surveillance Group, S42
Chajón, J. F., 528
Chan, L., 268
Chang, H. Y., S105
Chang, M.-H., 1163
Changchawalit, S., 141
Chaowagul, W., 561
Cheingsong-Popov, R., 256
Chen, I. S. Y., 369, 805
Chen, J.-Y., 1163
Chen, S., 1103
Chen, Y.-M. A., 805
Chesney, P. J., 1
Chi, E. Y., 306
Chia, J. K. S., 599
Chin, A. C., S188
Ching, W. T. W., 805
Chiphangwi, J. D., 1116
Chong, P., S86, S162
Chonmaitree, T., 590
Chou, C.-C., 1012
Chow, C.-B., 1111
Chow, T. P., 268
Chu, C.-M., 831
Chu, V. P., 585
Chua, K.-Y., S75
Ciccone, E., 917
Cirrincione, C., 960
Claesson, B. A., S205
Clancy, R. L., S194, S199
Classen, D. C., 14

INDEX TO VOLUME 165

Author Index

Abbott, S., 740
Abrams, J. S., 506
Abu Kwaik, Y., S195
Achtman, M., 53
Adderson, E. E., S57
Agis, F., 369
Agoki, E., 949
Ahlm, C., 934
Ahmed, F., 161
Ahmed, M. A., S201
Ahrne, H., 994
Aiyappa, A., 585
Ajello, L., 175
Alary, M., 565
Alberti, A., 181
Albus, A., 749
Alexander, L. K., 134
Alexandrescu, C., S115
Al-Ghassani, A. A. K., 444
Alley, E. S., 964
Allred, D. P., 175
Alm, B., S38
Almeido-Hill, J., S129, S144
Alpert, G., 494
Al-Waili, N. S. D., 1170
Amako, K., 183
Ampel, N. M., 710
Anaissie, E. J., 1155
Anders, J., S114
Andersen, L. I., 389
Anderson, E. L., 727
Anderson, E. C., 1069
Anderson, L. J., 456
Anderson, P., S110, S160
Anderson, R., 456
Anderson, S. K., 749
Andersson, B., 994, S38
Andersson, J., 994
Andrac, L., 778
Aniansson, G., S38
Antonelli, G., 593
Anttila, M., S36
Apicella, M. A., S195, S198, S203
Appleyard, M., 389
Arana, B. A., 518, 528
Arana, F. E., 528
Araujo, F. G., 788
Arcia, J., 93
Arencibia-Mireles, O., 644
Argani, I., 155
Argyle, J. C., 644
Armbruster, C., 783
Armstrong, D., 960
Artini, M., 180
Arvin, A. M., 119, 852
Asher, L. V. S., 835
Ashley, R., 813
Atkinson, W. L., 920
Aujard, Y., 147, 569
Axelrod, H. R., 757
Bach, J. F., 364
Badaró, R., 535, 1094
Baddour, L. M., 749
Baden, H. P., 968
Badolato, M. C., 180
Bailey, C. C., 886
Bailey, T. C., 548
Bakaletz, L. O., S196, S201
Baker, P. J., S44
Baker-Zander, S. A., 69, 396
Baldwin, G., 494
Balis, F. M., 99
Balsano, C., 180
Band, H., 506
Banks, R., 886
Barbaree, J. M., 736
Barenkamp, S. J., S181
Baric, R. S., 134
Barnes, P. F., 506
Barral, A., 535, 1094
Barral-Netto, M., 535
Barre-Sinoussi, F., 364
Barrett, T. J., 979
Barthold, S. W., 471
Bartlett, J. G., 913
Bartlett, M. S., 764
Bartok, A. E., 93
Bary, M., 364
Baudry, B., 141
Bauer, D., S74
Baughn, R., 553
Baur, A., 419
Baylor, N. W., 433
Beati, L., 1167
Beddows, S., 256
Beier, P. L., 819
Bejarano, G. C., 710
Bektesh, S., S106
Belshe, R. B., 727
Benach, J. L., 658
Benhamou, J. P., 595, 723, 1164
Benson, A., 987
Benson, R. F., 736
Berggren, T., 299
Bergmann, K. F., 929
Berland, R., 1127
Berman, J. D., 528, 764, 968
Bermudez, L. E., 75
Bernard, E., 787
Bernuau, J., 595
Berzofsky, J. A., 1012
Betts, J., 865
Beuvery, E. C., S152
Bienzle, U., 501
Bijlmer, H. A., S29
Bingen, E., 147, 569
Binn, L. N., 835
Bitran, J. D., 793
Bittker, S., 155
Bjermer, L., 934
Black, S. B., S139
Blanchard, D. K., 702
Blaney, S. M., 99
Blaser, J., 281
Blattner, W. A., 268, 920
Blevins, A., 960
Blitstein-Willinger, E., 501
Block, C., 785
Blok, W. L., 898
Blot, P., 147
Bodey, G. P., 1155
Boersma, W. G., 397
Bohnsack, J. F., 315
Boissinot, C., 147
Bolard, J., 337
Bollinger, R. C., Jr., 913
Bonner, D. P., 732
Bonnez, W., 376
Boone, T., 689
Bosley, G., S34
Bothamley, G. H., 598
Boucher, C. A. B., 105
Bourgeault, J., 908
Boutonnier, A., 1064
Bowden, R. A., 972
Boyer, K. M., 1049
Boyer, N., 723
Bozzette, S. A., 93
Braddick, M., 262
Bradley, D. W., 835, 1001
Brahimi, N., 147, 569
Brandtzaeg, P., S167
Brasini, A., 779
Brazilian Purpuric Fever Study Group, S16
Brechot, C., 720
Breider, M. A., 651
Breiman, R. F., 736
Briles, D. E., 671
Brockhaus, W., 419
Brodeur, B., S86
Brodeur, B. R., S162
Brogan, S., 444
Bronson, R. T., 846
Broome, C. V., S34
Brotman, B., 438
Brouwers, P., 99
Brown, J. M., 175
Bruce, A. W., 1142
Brunham, R. C., 1076
Bryant, R. E., 676
Bucher, D., 155
Burchett, S. K., 813
Burke, D. S., 185
Burke, J. P., 14
Burns, J., 456
Burroughs, M., S82
Butler, J., 716
Butler, K. M., 99
Butler, P. D., S90
Buurman, W. A., 898
Byrd, L. T., 1082
Byrd, R. G., 638
Cabellos, C., S82
Cadman, E. C., 781
Cal, S. X., 1082
Callow, D., 256
Callow, M. G., S75
Campbell, C. H., Jr., 251
Candler, E., Jr., 623
Canessa, A., 1168
Cannon, R. O., 251, 920, 1124
Cao, C. X., 322
Carbon, C., 337
Carl, M., 1145
Carl, M., 581, 1001
Carlson, E., 1056
Carlsson, M., 994
Carman, W. F., 127
Carrigan, D. R., 925
Carroll, W. L., S57
Carvalho, E. M., 535, 1094
Casadevall, A., 1086
Castellazzo, A., S198
Cate, T., 553
Cates, K. L., 942, S70
Caudill, J. D., 835
Caugant, D. A., 46
CDC Meningitis Surveillance Group, S42
Chajón, J. F., 528
Chan, L., 268
Chang, H. Y., S105
Chang, M.-H., 1163
Changchawalit, S., 141
Chaowagul, W., 561
Cheingsong-Popov, R., 256
Chen, I. S. Y., 369, 805
Chen, J.-Y., 1163
Chen, S., 1103
Chen, Y.-M. A., 805
Chesney, P. J., 1
Chi, E. Y., 306
Chia, J. K. S., 599
Chin, A. C., S188
Ching, W. T. W., 805
Chiphangwi, J. D., 1116
Chong, P., S86, S162
Chonmaitree, T., 590
Chou, C.-C., 1012
Chow, C.-B., 1111
Chow, T. P., 268
Chu, C.-M., 831
Chu, V. P., 585
Chua, K.-Y., S75
Ciccone, E., 917
Cirrincione, C., 960
Claesson, B. A., S205
Clancy, R. L., S194, S199
Classen, D. C., 14

Clausen, C., 740
Clemens, J. D., 161
Clements, D. A., S11, S33
Clements, J. F., S7
Clerici, M., 1012
Cloninger, L. A., 716
Co, S., 599
Cochi, S. L., 444
Cohen, D., 785
Cohen, J., 591
Cohrs, R., 619
Coker, R., 593
Cole, P., S100
Coleman, J. L., 658
Comité des Anti-Viraux, 723
Cone, L. A., 638
Conly, J., 761
Connolly, P. J., 793
Constantine, N. T., 256
Conti, M., 720
Cooper, J. D., 548
Cooperstock, M., 393
Corbett, C. E. P., 976
Cordero, M., 398
Cordle, C. T., 623
Corey, L., 813
Corn, P. G., S114
Corriveau, A., 908
Coulson, N., 1145
Coulton, J. W., S188
Courouce, A. M., 364, 369
Coutinho, R. A., 427
Crain, M. J., 671
Crawford, D. D., 891
Cripps, A. W., S194, S199
Crofoot, G., 553
Crook, D. W., 1069
Cross, E., 716
Crossley, K. B., 1
Croteau, C., 775
Crowe, B., 53
Cryz, S., 1042
Cunningham, A. L., 150
Curfs, J. H. A. J., 898
Currenti, M., 593
Dadzie, K. Y., 964
Dale, D. C., 689
D'Alessio, D. D., 1133
Dallabetta, G. A., 1116
Daly, R., 185
Dance, D. A. B., 561
Darby, G., 105
Datta, P., 262
Daum, R. S., S1
Davis, B., 975
Dawson, G. J., 1006
D'Costa, L. J., 949
Dean, R. A., 764
Dearlove, C. E., 182
Deaver, K., S34
De Bac, C., 180
Deckard, G. J., 224
De Fraites, R., 557
de Goede, R. E. Y., 427
Degos, F., 723
Degott, C., 723
Del Bono, V., 1168
Dellamonica, P., 787
de Man, P., 46
De Maria, A., 917
DeMaria, T. F., S196
de Martino, M., 394
De Marzio, E., 180
Denamur, E., 147, 569
Denizot, Y., 589
Densen, P., 942, S70
DePamphilis, J., 775
Deringer, J. R., 1056
De Sole, G., 964
de Souza, M. S., 471
Devi, S. J. N., 1086
Devlin, M. E., 619
de Wolf, F., 413
Dianzani, F., 593
Dimopoulou, I. D., 1069
Dinarello, C. A., 1094
Dixon, J. M. S., 671
Djeu, J. Y., 702
Doinel, C., 364
Dorovini-Zis, K., 865
Drancourt, M., 1167
Duarte, M. I. S., 976
Dueland, A. N., 619
Durand, J. M., 778
Durant, J., 787
Eberhard, M. L., 1158
Eberlein, B., 419
Echeverria, P., 141, 144, 557, 744, 1042
Edelson, P. J., S74
Edlin, B. R., 793
Edlind, T. D., S118
Edwards, S., 134
Ehrenfeld, E., 273
Eickhoff, T. C., 201
Eickmann, K., 53
Eisner, W., 1056
El-Bualy, M. S., 444
Eling, W. M. C., 898
Elion, J., 147, 569
Ellis, W. Y., 764
Ellner, J. J., 179
El-Tigani, A., 1001
Embree, J. E., 262
Endert, E., 413
Engle, R., 1006
Engler, W. F., 835
Englund, J. A., S134
Ennis, F. A., 545
Epstein, J. S., 155
Erlinger, S., 595, 723
Eschenbach, D. A., 393
Eskola, J., S2, S137, S165
Ettinger, N. A., 548
European Organization for Research and Treatment of Cancer, 591
Evans, S. W., 886
Evenberg, D., S152
Fairley, C. K., 1103
Falcao, O., S134
Falkow, S., S117
Fann, S. A., 577
Farah, S., 761
Farci, P., 1006
Farley, M. M., S42, S109, S111
Farley, T. A., 613, 736
Fattovich, G., 181
Fausti, S. A., 1026
Ferguson, D. J. P., S115
Ferrao, M., 127
Ferrazin, A., 917
Ferren-Gardner, C., 456
Ferrini, S., 917
Field, A. K., 732
Field Services Branch, 87
Fikrig, E., 471, 1127
Finlay, B. B., 865
Finnish-Moroccan Study Group, 385
Fireman, B., S139
Fischer, P., 479
Flack, F. S., S75
Flanigan, T. P., 772
Flavell, R. A., 471, 1127
Fleisher, G. R., 494
Flores, J., 826
Fong, Y., 859
Foote, N., 799
Forney, L. J., 464, S105, S106, S201
Forrest, B. D., 182
Forsberg, P., 994
Forseter, G., 155
Foung, S. K. H., 268
Fournier, J.-M., 1064
Fox, K., 676
Francis, H. L., 913
Franklin, R., S34
Frederiksen, H-J., 389
Frey, E. A., 865
Frey, R. H., 1026
Frissen, P. H. Jos, 413
Fu, T., 433
Fuchs, D., 783
Fujimoto, S., 183
Fujimura, M., 957
Fundaró, C., 394
Galgiani, J. N., 710
Gallo, D., 268
Garaev, M. M., 256
Garcia, F. U., 1138
Garland, S. M., 1103
Gauny, S. S., 26
Gay, V., 394
Geffin, R. B., 111
Gelfand, J. A., 1094
Gelnett, J., 557
Geratz, J. D., 134
Gerin, J. L., 929
Gershenwald, J., 859
Geslin, P., 569
Gigliotti, F., 329
Gilbert, C. C., 891
Gilbert, G. L., S33
Gilden, D. H., 619
Gilks, C., 256
Gillis, Z., 494
Gilsdorf, J. R., 464, S105, S106
Giorgi, J. V., 1012
Givner, L. B., 938
Glaser, J. B., 589
Glasser, D., 251
Gleaves, C. A., 987
Glezen, W. P., S134
Gnann, J. W., Jr., 450
Goldberger, M. J., 179
Gonin, R., 456
Goodman, L. J., 667
Gotz, T. D., 667
Gordien, E., 369
Gotoff, S. P., 1049
Goudsmit, J., 105, 413
Grankvist, O., 934
Granoff, D. M., S7, S66, S121
Grant, J. A., 590
Grass, S., S86
Gray, S., 716
Gray-Owen, S., S103
Grayston, J. T., 184
Green, M. S., 785
Green, M., 166, 170
Greene, B. M., 1161
Greenwood, B., S26
Greifinger, R., 589
Gress, J., 99
Grierson, J. M., 150
Griffioen, A. W., S71
Grigg, A., 972
Grisso, C. L., 506
Groopman, J. E., 1119
Groover, J., 553
Groseclose, S. L., 541
Grundmann, H.-J., 501
Gudeman, V. K., 1012
Guelde, G., 34
Guenounou, M., 873
Guise, I. A., S33
Gupta, P., 1012
Gustin, J. N., 315
Gyorkos, T. W., 908
Haberberger, R. L., 557
Hachem, R., 1155
Hackett, S. P., 879
Hackman, R., 987
Hadlock, K. G., 268
Haemophilus influenzae Study Group, S34
Hähnle, U., 501
Haley, K., 775
Hamel, J., S162
Hamory, B. H., 205, 218, 224
Handsfield, H. H., 1020
Hansen, E. J., 484, 644, S119, S185
Hanson, C. V., 268
Hardin, J. A., 1127
Harrer, T., 419
Harrington, R. D., 987
Harvey, R. C., S42

Hasan, N. U., 1170
Hassan-King, M., 53
Haubrich, R. H., 545
Havlik, J. A., Jr., 577
Hawkins, M. E., 99
Hawkins, R., 1145
Hawkins, R. E., 581, 716
Hay, J., 852
Hayden, F., 450
He, S. H., 344
He, W., 859
Healey, M. C., 769
Hegenscheid, B., 501
Heijnen, C. J., S161
Heiler, M., 479
Heimer, R., 781
Hellman, L., 761
Hemming, V. G., 456
Heney, D., 886
Henry, J. A., 1026
Herwaldt, B. L., 518, 968
Hetherington, S. V., 753
Hewlett, I. K., 155
Hiatt, R., S139
Hicks, L. L., 205, 218, 224
Hill, H. R., 315
Hill, N. L., 1107
Hillier, S. L., 393
Hinkley, C. M., S134
Hinthorn, D., 450
Hitchman, D., 904
Ho, D. D., 805
Ho, H.-N., 1012
Ho, J. L., 344, 1094
Hoeger, P. H., 1064
Hoffenberg, E. J., 1107
Hoffner, S. E., 179
Hoge, C., 1042
Hoge, C. W., 736
Hoiseth, S. K., S114
Hoke, C. H., Jr., 631, 835
Holloway, Y., 397
Holmes, K. K., 262
Holmes, S. J., S66, S121
Hoogerhout, P., S152
Hook, E. W., III, 251, 541, 920, 1124
Hooton, T. M., 987
Hoover, D., 1116
Hoover, R. L., 1138
Horan, J. M., 613
Horner, P. J., 593
Horsburgh, C. R., Jr., 577
Hsu, C.-Y., 1163
Huang, J.-L., 732
Huang, L.-M., 1163
Huda, S., 161
Hugo, H., 994
Huguenel, E. D., 1127
Huima, T., 438
Hurley, M. K., 585
Hussain, M. A. M., 1001
Husson, R. N., 99
Huth, T. S., 14
Hutterer, J., 783
Hutto, C., 111
Huycke, M. M., 1133
Hyams, K. C., 716, 1001
IDSA Manpower and Training Committee, 205, 218
Ihara, T., 158
Illisituk, S., 908
Inchauspé, G., 438
International Antimicrobial Therapy Cooperative Group, 591
Intralawan, P., 631
Ishida, M., 373
Ito, M., 158
Itoh, T., 183
J5 Study Group, 695
Jackson, J. J., 1033
Jacobsen, F., 99
Jaffery, M., 438
Jahn, G., 419
Jarosinski, P., 99
Jennings, H., S156
Jerse, A. E., 979
Jia, X. Y., 273
Jianfu, W., 53
Jiang, S., 777
Jo, T., 957
Jockusch, J. D., 1082
Johns, M. A., 953
Johnson, J., 761
Johnson, J. R., 299
Johnson, R. T., 631
Johnson, W. D., Jr., 535, 1094
Joly, J. R., 565
Joly, V., 337
Jongsawas, V., 631
Joshi, B., 155
Juto, P., 934
Kaleebu, P., 256
Kalimo, H., 596
Kamiya, H., 158
Kamiya, T., 158
Kaper, J. B., 979, 1042
Kaplan, E. H., 781
Kaplan, E., 953
Kaplanski, G., 778
Karstorp, A., 994
Kaur, M., 1001
Kaye, E. T., 968
Käyhty, H., S115, S137, S165
Kellam, P., 105
Kelso, K. Y., 613
Kilian, M., S192
Kinchington, P. E., 852
Kirkbright, E., 757
Kitajima, H., 957
Kitamura, K., 158
Klebanoff, S. J., 19
Klegerman, M. E., 1049
Kline, R. L., 913
Klotman, M. E., 891
Knowlton, D. R., 161
Knox, K. K., 925
Koff, W., 545
Kolattukudy, P. E., S201
Koles, N. L., 34
Kolonoski, P., 75
Komada, Y., 158
Komaroff, A. L., 184
Komase, K., 186
Kopp, S. M., 638
Korba, B. E., 929
Korn, K., 419
Kornbluth, R. S., 80
Koropchak, C. M., 119
Korvick, J. A., 352
Kosseim, M. L., 1076
Kovacs, J. A., 1151
Koyanagi, Y., 973
Kraak, W. A. G., 1069
Krawczynski, K., 835, 1001
Kreiss, J. K., 262
Kreiswirth, B. N., 1056
Krijnen, P., 413
Krogstad, P., 740
Krohn, M. A., 393
Kroll, J. S., S93
Kropp, H., 1033
Kuchler, M., 757
Kuller, L., 1020
Kuo, P.-F., 1163
Kuratana, M., S110
Kurikka, S., 977
Kuritzkes, D. R., 805
Kusecek, B., 53
Kuttschrütter, H., 397
Kuvanont, K., 1042
Kwiatkowski, D., 561
Kyrönseppä, H., 385
La Brooy, J. T., 182
Lacke, C., 553
LaForce, F. M., 1
Lagergård, T., S205
Lahart, C., 553
Lai, C. L., 127
Lai, S., 111
Lambert-Zechovsky, N., 147, 569
Lammie, P. J., 1158
Lange, J. M. A., 105, 413, 427
Larder, B. A., 105
Larsen, R. A., 14
Larsson, P., S38
Larzul, D., 595, 1164
Lassiter, H. A., 290
Lau, S., 689
Lau, Y.-L., 1111
Law, B. J., 262
Law, C. L. H., 150
Lazzarin, A., 720
Lebech, A.-M., 982
Lebech, M., 982
Lecce, R., 180
Ledesma-Medina, J., 166
LeDuc, J. W., 835
Lee, C.-Y., 1163
Lee, F. F., 251
Lee, J. C., 749
Lee, J., 184
Lee, M. L., 393
Lee, P. K., 1056
Lefevre, P., 778
Le Fichoux, Y., 787
Lefrere, J. J., 364
Lefrère, J. J., 369
Legenne, P., 1155
Legrand, C., 1155
Lehmann, D., S20
Lenaour, R., 873
Lenkei, R., 994
Lenz, W., 1064
Lepore, T. J., 968
Lepow, M. L., 753
Lerman, Y., 785
Lerner, S. A., 683
Lesse, A. J., S119
Leszczynski, J., 456
Letson, G. W., S144
Lett-Brown, M., 590
Leung, T.-H., 1111
Levine, D. P., 683
Levine, M. M., 141, 1042
Levine, R. P., 942, S70
Levrero, M., 180
Lewis, D. B., 740
Lewis, D., 716
Lewis, I. J., 886
Lewis, J. S., 573
Lexomboon, U., 144
Liao, M.-J., 757
Liaw, Y.-F., 831
Lidin-Janson, G., 46
Lim, D. J., S201
Lim, D. J., S196
Lim, Y. L., 1042
Linde, A., 994
Linderholm, M., 934
Lindwall, A., 994
Liomba, G., 1116
Lipinski, A. E., 671
Lipka, J. J., 268
LiPuma, J. J., S118
Liu, C., 450
Lockman, J., S70
Lockman, J. C., 942
Loeb, M. R., S110
Loftenius, A., 994
Lok, A. S. F., 127
London, W. T., 1006
Losonsky, G., 1042
Losonsky, G. A., 826
Lowe, J., 1145
Lowrance, C., 749
Lowrance, J. H., 749
Lowry, S. F., 859
Lubick, C., 787
Lukehart, S., 396
Lukehart, S. A., 69, 1020
Lundgren, B., 1151
Lundgren, J. D., 1151
Luo, K.-X., 777
Lutz, B., 920

Ma, O. C. K., 127
Maassab, H. F., 727
Macchi, G., 784
MacInnes, S. J., S33
Maciver, I., 644
Maclean, I., 1076
MacLean, J. D., 908
Magruder, C. H., 175
Mahalingam, R., 619
Mahoney, F. J., 613, 736
Maisonneuve, P., 720
Mäkelä, O., 977
Mäkelä, P. H., 977, S2, S137, S165
Makino, S., 186
Malankar, P. G., 444
Malone, J. D., 716
Malone, J. L., 185
Mandine, E., 873
Manivel, J. C., 299
Mann, J. M., 245
Marano, M. A., 859
Marcellin, P., 595, 723, 1164
Mariano, O. N., 976
Mariotti, M., 369
Marra, C. M., 396, 1020
Marrs, C. F., S105, S106
Marshall, G. S., 381
Marshall, R. J., 772
Martin, B. A., 667
Martin, D., S86, S162
Martin, T. R., 306
Martinot-Peignoux, M., 595, 1164
Marx, J. J., 1133
Mascaró, C., 789
Maskell, D. J., S90
Master, M., 111
Masterson, J. G., 413
Masullo, C., 784
Mathiesen, L., 982, 1151
Matsuzaki, N., 957
Mattila, L., 385
Mattlinger, B., 364
Matuschka, F.-R., 479
Mayer, L., S111
McCarthy, M. C., 1001
McClean, K. L., 904
McCracken, G. H., Jr., 644
McCray, E., 87
McCrea, K. W., S105, S106
McCutchan, J. A., 93
McDonald, W. J., 1026
McFarland, L. M., 613, 736
McGlynn, L. M., 93
McGowan, J. E., Jr., 1
McGroarty, J. A., 1142
McIntosh, K., 456, 846
McLaughlin, R. E., S195
McManus, T. J., 799
McNagny, S. E., 573
McNeal, M., 161
McNeil, J. J., 1103
McNeil, M. M., 175
Mendelman, P. M., 740, S107
Mensing, T. L., 835
Mertz, G. J., 450
Metchock, B., 577
Meyers, J. D., 987
Meylan, P. R. A., 80
Michaels, M. G., 170
Michelini-Norris, M. B., 702
Miedema, F., 427
Migasena, S., 1042
Miletich, F., 1168
Milhous, W. K., 764
Miller, R. D., 290
Miller, V. L., 740
Mills, J., 592
Miotti, P. G., 1116
Mitroka, J. G., 732
Miyoshi, I., 268
Modlin, R. L., 506
Moellering, R. C., Jr., 229
Mohan, K. M., 813
Moldawer, L. L., 859
Mondain, V., 787
Monforte, A. d'A., 720
Mooi, F. R., S97
Moore, J. L., 793
Moore, P. S., 53
Moore, R. D., 683
Morelli, G., 53
Moretta, L., 917
Mori, T., 186
Morthland, V. H., 676
Morton, W. R., 1020
Moss, M. W., 913
Mosseri, R., 953
Moxon, E. R., S62, S77, S90, S115
Mukherjee, J., 1086
Mulder, J. W., 105, 413
Mulhall, B., 150
Müller, C., 929
Munis, J. R., 80
Muñoz, M. R., 398
Munson, R., Jr., S86
Muro, A., 398
Murphy, G. S., 557
Murphy, T. F., S203
Murphy, T. V., S7
Murray, H. W., 513
Musher, D. M., 553
Myers, S. S., 781
Nader, S., 852
Nagae, M., 373
Nahass, R. G., 775
Nahm, M. H., S53
Nahmias, A. J., 251
Nakagawa, M., 186
Nakano, T., 158
Nakata, M. M., 599
Nakayama, M., 957
Nakayama, T., 186
Nash, R., 689
Nathan, N., 589
National Cancer Institute of Canada—Clinical Trials Group, 591
Navin, T. R., 518, 528
Ndinya-Achola, J. O., 262, 949
Nelsing, S., 982
Nelson, M. B., S203
Nelson, P., 1155
Nelson, W. M., 1145
Nerome, K., 373
Nerome, R., 373
Netto, M. B., 1094
Neu, H. C., 322
Newcomer, W., S144
Newman, F. K., 727
NIAID Collaborative Antiviral Study Group, 450
Nichols, W. W., 1069
Nie, J., 777
Nielsen, J. O., 1151
Nielsen, T., 1151
Nightingale, S. D., 1082
Nisalak, A., 631
Nishanian, P. G., 1012
Noel, G. J., S74
Norgard, M. V., 484
Novati, R., 720
Novick, R. P., 1056
Novitsky, T. J., 494
Nugent, S. L., 727
Nutman, T. B., 1162
Nylén, O., S38
O'Brian, J., 185
Offit, P. A., 1107
Oh, G., 676
Oishi, K., 34
Oka, S., 186
Okayasu, I., 973
Oksanen, P., 385
Oksi, J., 596
Olchowy, T. W. J., 651
Oldfield, E. C., III, 185
Oliveira, M. S., 976
Olsen, S., 732
Olson, D. J., 1026
Ombette, J., 949
Onorato, I. M., 87
Oppenheimer-Marks, N., 484
Orskov, F., 141
Orskov, I., 141
Osano, M., 373
Osborne, B., 987
Osborne, W., 689
Osterholm, M. T., S7
O'Sullivan, E., 105
Osuna, A., 789
Ou, C.-Y., 793
Oxman, M., 450
Pagliari, C., 976
Palomba, E., 394
Pamba, H., 262
Pan, A. A., 585
Panackal, P. A., 1107
Pao, C.-C, 831
Paraskevas, M., 1076
Parenti, D. M., 179
Parker, C. J., 315
Parker, R. M., 573
Parkhurst, G. W., 667
Parks, W. P., 111
Parsonnet, J., 494
Pascual, D., 438
Pastor, P., S7
Patriarca, P. A., 444
Patrick, D., 865
Peakman, M., 799
Pearson, C. A., 702
Pedral-Sampaio, D., 535
Peeling, R., 1076
Peeters, C. C. A. M., S161
Peltola, H., 385, S2, S36, S137, S165
Peltonen, R., 596
Pena-Cruz, V., 456
Peña-Cruz, V., 846
Perera, M. L., 398
Perfect, J. R., 891
Perugini, L., 394
Peters, W. P., 891
Petersen, E., 982
Peterson, H., S38
Petrascu, I. V., 256
Petrofsky, M., 75
Petruccelli, B. P., 557
Phillips, G., 972
Pia, E. S., 1107
Piazza, D., 26
Pichichero, M. E., 826, S160
Pierce, R., S34
Pierson, L. M., S7
Pigott, N., S34
Pinier, Y., 787
Piot, P., 262
Pistoia, V., 1168
Pitisuttitham, P., 1042
Pizzo, P. A., 99
Plourde, P. J., 949
Plummer, F. A., 262, 949
Pocchiari, M., 784
Pohl, C., 166
Poirier, L., 908
Pollack, M., 34
Pollard, R. B., 450
Pond, D. G., 1142
Poolman, J. T., S152, S161
Poolsuppasit, S., 631
Pope, J. H., 819
Poplack, D. G., 99
Porat, R., 953
Porcelli, S., S160
Poulsen, K., S192
Powderly, W. G., 548
Pradier, C., 787
Prameya, R., 865
Prasad, S., S82
Preston, F. M., 819
Prince, A. M., 438
Principi, N., 720
Projan, S. J., 1056

Prokocimer, P., 788
Prou, O., 369
Proulx, C., S86
Proulx, J.-F., 908
Provost, V., 541
Purcell, R. H., 1006
Purdy, M. A., 1001
Qassim, M., 150
Quagliarello, V. J., S119
Quale, J. M., 981
Queener, S. F., 764
Quinn, A., S57
Quinn, F. D., S111
Quinn, J. P., 667
Quinn, M. A., 1103
Quinn, T. C., 251, 541, 913, 920, 1124
Rabalais, G. P., 381
Rabe, L. K., 393
Radolf, J. D., 484
Rahn, D. W., 1127
Räisänen, S., 1148
Ramautarsing, C., 105
Ramilo, O., 644
Rao, M. R., 161
Raoult, D., 1167
Rasmussen, K. R., 769
Rea, T. H., 506
Read, R., S100
Realdi, G., 181
Reed, S. G., 1094
Reese, D., 981
Reichman, R. C., 376
Reid, G. R., S129
Reid, G., 1142
Reid, R., S144
Reiss, C. S., 846
Remington, J. S., 788
Remme, J., 964
Rennie, R., 761
Reyes, G. R., 268
Rey-Martinez, J., 775
Rhodes, L. L., Jr., 835
Richard, M. A., 778
Richman, D. D., 80, 93
Richter, D., 479
Rickman, L. S., 581
Rignér, P., S38
Rijkers, G. T., S71, S152, S161
Riley, B. S., 484
Rimer, H. C., 826
Rios, M. J. C., 344
Riva, E., 593
Rivin, B., S144
Robbins, J. B., 1086
Roberts, J. M., 1158
Robertson, D. L., 1145
Rocha, H., 535
Rodriquez-Barradas, M. C., 553
Romano, L., 779
Rompalo, A. M., 1124
Ronald, A. R., 949
Roos, M. T. L., 427
Rosales, M. J., 789
Rose, R. C., 376
Rose, R. M., 775
Rosenberg, G. B., 585
Rosner, G. L., 891
Rosser, S. W., S119
Rouger, P., 364, 369
Rouzioux, C., 364
Rozmajzl, P. J., 716
Rubens, C. E., 306, 315
Ruol, A., 181
Ruscetti, F. W., 433
Ruyechan, W. T., 852
Ruzinski, J. T., 306
Saah, A. J., 1116
Saarinen, L., S165
Sack, D. A., 161
Safrin, S., 592
Sahlmüller, G., 501
Saif, L. J., 623
Saimot, A. G., 723
St. Geme, J. W., III, S117
Saint-Julien, L., 337
Saint-Pierre-Chazalet, M., 337
Saji, F., 957
Sakurai, M., 158
Salas, S. D., 710
Säll, C., 994
Salo, P., 385
Salomaa, P., 596
Samore, M. H., 945
Sanchez, J. L., 557
Sanders, L., S71
Santosham, M., S129, S144
Sarvas, H., 977
Sasaki, K., 186
Saul, R. A., 175
Scadden, D. T., 1119
Schaffer, H. I., 1026
Schaller, J. P., 623
Scharff, M. D., 1086
Scheld, W. M., S119
Schellekens, H., 1166
Schellekens, P. T. A., 427
Schiff, G., 161
Schlievert, P. M., 638, 1056
Schneerson, R., 1086
Schock, G. J. H., 585
Schooley, R. T., 805
Schreuder, G. M. T., 598
Schryvers, A. B., S103
Schulz, K., 638
Schwartz, A., 1094
Scott, G. B., 111
Scott, M. G., S53
Scott, W. A., 111
Segreti, J., 667
Sekla, L., 262
Senaldi, G., 799
Senyk, G., 26
Seppälä, I. J. T., 977
Serichantalerg, O., 141
Serichantalergs, O., 144
Sethabutr, O., 144
Settergren, B., 934
Shackelford, P. G., S57
Shafran, S. D., 904
Sharetzsky, C., S118
Sharma, S. A., 651
Sharp, M., 119, 852
Shaunak, S., 256
Shaw, G. M., 268
Shearer, G. M., 1012
Shearlock, K. T., 175
Sheen, I-S., 831
Shero, M., S198
Shibolet, S., 953
Shikanai-Yasuda, M. A., 976
Shimoya, K., 957
Shinefield, H. R., S139
Shriver, D., S134
Siber, G. R., 456, 494, 775, 945, S129, S134, S144
Siitonen, A., 385
Sikes, R. K., S42
Silverstein, S. C., 322
Silvestri, R. C., 775
Simms, T. E., 185
Simón, F., 398
Simula, I., 385
Singharaj, P., 1042
Six, H. R., S134
Sjogren, M. H., 835
Skurnik, M., 596
Slack, M. P. E., 1069
Slaney, L. A., 949
Slatter, V., 396
Slepon, R., 785
Small, J. D., 134
Smets, P., 873
Smith, A. L., 471
Smith, B. L., 1056
Smith, G., 545
Smith, J. W., 764
Smith, K. L., 623
Snijder, J. A. M., 397
Sobel, J., 1094
Soike, K., 732
Sonneborn, H. H., 419
Soong, S.-J., 450
Soubeyrand, J., 778
Southern, P. M., 1082
Spector, S. A., 93
Spellman, P., S111
Spence, M., 541
Spielman, A., 479
Spinola, S. M., S195, S198
Stackiw, W., 262
Starzl, T. E., 170
Staudt, M., 908
Steel, C., 1162
Stein, D. S., 352
Stein, K. E., S49
Steinberg, T. H., 322
Stenfors, L.-E., 1148
Stenvik, M., 385
Stephens, D. S., S42, S109, S111
Stevens, D. L., 879
Stevens, L. E., 14
Stevens, P., 26
Storch, G. A., 548, 987
Stouffer, B., 732
Stout, G. G., 381
Stull, T. L., S118
Su-Arehawaratana, P., 1042
Sugaya, N., 373
Suleiman, A. J. M., 444
Sullivan, K., 972
Summers, D. F., 273
Suputtamongkol, Y., 561
Sutter, R. W., 444
Svanborg, C., 46, S38
Svanborg, M., S38
Svenson, S. B., 994
Swerdel, M., 732
Swierkosz, E. M., 727
Szabo, M. J., S90
Tabrizi, S. N., 1103
Tagger, A., 181
Takakura, C. F. H., 976
Takala, A. K., S2, S11, S137
Takamatsu, K., 973
Takeda, A., 545
Takeuchi, Y., 373
Taliani, G., 180
Talkington, D. F., 671
Tamura, K., 144
Taniguchi, T., 957
Tanizawa, O., 957
Tanner, J. E., 290
Tarasevich, I., 1167
Tärnvik, A., 934
Tartaglione, T. A., 396
Taylor, D. N., 557, 1042
Taylor, D. C., S199
Teitelbaum, R. F., 513
Tenbergen-Meekes, A.-M., S161
Terada, K., 852
Terragna, A., 917
Tersmette, M., 427
Testa, D., 757
Thiers, V., 720
Thomas, H. C., 127
Thomas, W. R., S75
Thompson, C., 494, S129, S144
Thompson, S. E., III, 577
Ticehurst, J., 835
Ting, S. F., 119
Titball, R. W., 1145
Titsyakorn, U., 631
Toews, G. B., S185
Tomeczek, L., 1142
Toussaint-Gari, M., 787
Tovo, P.-A., 394
Trenholme, G. M., 667
Trepo, C., 778
Trofa, A., 1042
Trollfors, B., S205
Trulock, E. P., 548
Tu, J.-I., 732
Tunkel, A. R., S119
Tuomanen, E., S82
Tuomari, A. V., 732

Turck, M., 775
Turner, C., S134
Turriziani, O., 593
Unge, P., 974
Unhanand, M., 644
Unnasch, T. R., 964
Vacheron, F., 873
Vachon, V., S188
Valensin, P. E., 779
Vallari, D. S., 1006
van Alphen, L., S29, S97, S177
van Boeckel, C. A. A., S152
van Boom, J. H., S152
van den Bosch, L., 182
van der Meer, J. W. M., 898
van Ham, S. M., S97
van Loon, F. P. L., 161
Vaughn, D. W., 631
Vergani, D., 799
Vergères, P., 281
Vermund, S. H., 352, 581
Vetter, N., 783
Viard, J. P., 364
Viljanen, M. K., 596
Virji, M., S115
Vittecoq, D., 364
Vogels, M. T. E., 898
Vornhagen, R., 419
Vreede, R. W., 1166
Vuust, J., 982
Wachsmuth, I. K., 979
Wachter, H., 783
Wadell, G., 934
Wagner, K. F., 185
Wain-Hobson, S., 369
Wainwright, N., 494
Wald, E. R., 166, 170
Waldeyer, S. L., 381
Wall, R. A., 53
Wallace, F. J., S199
Wallner, G., 783
Walsh, E. E., 456
Waltman, W. D., II, 671
Walz, S., 557
Wamae, C. N., 1158
Wamola, I., 262
Wang, J.-D., 1163
Wang, L.-P., 777
Wang, S.-P., 184
Wang, Z., 1119
Ward, R. L., 161
Wasi, C., 256
Wasserman, S. S., 826, 1042
Watson, D., 553
Wattel, E., 369
Watts, D. M., 256
Weagent, S., 740
Weber, J. N., 256
Weinstein, R. A., 793
Wenger, J. D., S34, S42
Wenzel, R. P., 975
Westall, J., 813
Westblom, T. U., 974
Weyant, R. S., S111
Whaling, S. M., 793
Wheeler, J. G., 938
Whicher, J. T., 886
White, K. E., S7
White, M., 960
White, N. J., 561
Whitley, R. J., 450
Whitney, A. M., S111
Wick, E. A., 344
Wiktor, S. Z., 920
Williams, A. E., S90
Williams, P. P., 577
Wilson, A., 119, 852
Wilson, C. L., 740
Wilson, C. B., 306, 813
Wilson, R., S100
Wilson, S. A., 613
Winkelhake, J. L., 26
Winkelstein, J. A., S62
Winship, T. R., 623
Wispelwey, B., S119
Wojta, J., 1138
Wold, A. E., 46
Wolff, M., S129, S144
Wong, D. C. L., 464
Wong, D. C., 1006
Woodard, D. R., 638
Woodward, T. E., 235
Woody, J. N., 1145
Wormser, G. P., 155
Wright, K. A., 891
Wynne, B. A., 1082
Xi, Y. G., 784
Xu, L.-Z., 595, 1164
Yamaguchi, T., S196
Yamamoto, N., 973
Yamamoto, T., 744
Yan, Y.-D., 433
Yang, C.-S., 1163
Yang, L., 805
Yeni, P., 337
Yip, Y.-K., 757
Yokota, T., 744
Young, L. S., 75
Yuki, N., 183
Yurt, R. W., 859
Zacher, B., S129
Zack, J. A., 1012
Zalisz, R., 873
Zazzi, M., 779
Zegers, B. J. M., S161, S71
Zenilman, J. M., 573
Zhang, X.-Q., 805
Zhou, X., 315
Zimmerman, P. A., 964
Zollinger, W., 53
Zuijderwijk, M., 1166

Subject Index

Acid dissociation, to increase sensitivity of p24 antigen detection, 913
Acyclovir, versus vidarabine, for disseminated herpes zoster, 450
Adenovirus, infection, in pediatric liver transplant patients, 170
Adherence
  bacterial, to nasopharyngeal epithelium, 1148
  E. coli
    association with diarrhea, 141
    enteroaggregative, to human intestine and HeLa cells, 744
  H. influenzae
    fimbria-mediated, S97
    hemagglutinating pili, S105
    type b
      effect of pili-specific antibodies, 464
      enhanced, due to capsule loss, S117
AIDS
  CD4 lymphocyte count, as predictor of HIV disease progression, 352
  C. neoformans meningitis in, outcome, 960
  cryptococcosis in, liposomal amphotericin B for, 593
  ddI pharmacology, in children, 99
  dehydroepiandrosterone, as predictor for progression, 413
  global perspective, IDSA meeting presentation, 245
  Haemobartonella-like bacterial infection, ultrastructural pathology, 976
  passive immunotherapy for, 364
  toxic shock syndrome in, 638
  toxoplasmic encephalitis, serum IFN-γ levels, 1170
  zidovudine and IFN-α combination therapy for, 793
AIDS commentary, CD4 lymphocyte count as predictor of disease progression, 352
AIDS-related research, role of ID specialist in, 592
Allotype, G2m(23), role in antibody response to *H. influenzae* type b, S66
Amikacin, for *P. aeruginosa* and *S. epidermidis*, in vitro model, 281
Aminoglycoside
  8-aminoquinolones, for *P. carinii* pneumonia therapy or prophylaxis, 764
  versus aztreonam therapy, nephrotoxicity and ototoxicity, 683
  β-lactam enhancement of activity, in murine abscess model, 676
  ototoxicity, detection of, 1026
Amphotericin B
  for
    bone marrow transplantation, prophylaxis, 891
    Creuzfeldt-Jacob disease, treatment failure, 784
    cryptococcosis in AIDS, liposomal, 593
    systemic murine fusarial infection, 1155
  nephrotoxicity, effect of cholesterol depletion on, 337
  resistance in *C. albicans*, 761
Animal model
  coronavirus, myocarditis and congestive heart failure, 134
  C. parvum, experimental infection, in aged hamsters, 769
  F. solani, amphotericin B for, 1155
  H. influenzae infection
    effect of pertussis toxin on susceptibility, infant rat, 945
    noninvasive, pulmonary clearance, S185
    nontypeable
      otitis media, chinchilla, S196
      respiratory immunity, rat, S199
  hepatitis C virus, antibody response, chimpanzee, 1006
  hepatitis E virus, macaque and owl monkey, 835
  HPV-11, antibody-mediated neutralization, nude mouse, 376
  lung infection, adult and neonatal rat, 306
  Lyme disease, nonspecific lymphocyte proliferation, 471
  M. avium–M. intracellulare complex, disseminated infection, beige mouse, 75
  M. catarrhalis, pulmonary clearance, mouse, 644
  myocarditis and congestive heart failure, rabbit, 134
  neonatal sepsis, due to group B streptococci, rat, 938
  N. meningitidis, endotoxin shock, rabbit, 494
  polymicrobic abscess, aminoglycoside activity, mouse, 676
  rotavirus diarrhea, gnotobiotic piglet, 623
  S. aureus endocarditis, rat, 749
  Sendai virus pneumonia, pulmonary histopathology, protein-deprived mouse, 846
  septic shock, LPS-treated mouse, 501
  syphilis and SIV infection, macaque, 1020
  TSST-1, sequencing of variant toxins, rabbit model, 1056
  urinary tract infection, histopathology, mouse, 299
  varicella virus, BV-araU for, monkey, 727
Antibiotic resistance, of *H. influenzae*, molecular epidemiology, 1069
Antibody
  profiles, in HIV infection, 419
  secretory, production patterns in mucosae, S167
Antibody to
  B. burgdorferi, prevalence, by IFA, ELISA, and Western blot, 1133
  glycoprotein B of HCMV, 381
  group B streptococcal C5a-ase, 315
  hepatitis A virus, nonstructural protein, 273
  hepatitis C virus, in chimpanzee, 1006
  hepatitis E virus, 1001
  H. influenzae type b
    affinity to polyribosyl phosphate, 753
    polysaccharide, S44, S49, S53
    vaccine, S121, S129, S134, S137, S139, S144, S152, S156, S160, S161, S162, S165
  HIV, quantitative analysis, 111
  HTLV-I and -II, unique epitopes, 268
  IFN, absence in patients treated with IFN, 757
  measles, in HIV infection, 589
  M. tuberculosis, 598
  OSPA and -B, for serologic diagnosis of Lyme disease, 1127
  P. carinii, in HIV infection, 1151
  rotavirus, correlation with risk, 161
  tetanus toxoid, in infants, 977
  Ty21a-based typhoid-cholera hybrid, oral, 182
Antibody-dependent cellular cytotoxicity, HTLV-I and -II, 805
Antigens, expressed by *N. meningitidis* serogroup A, 53
Asthma, virus-induced, role of PAF in, 589, 590
Astrakhan fever, genomic identification of rickettsia, 1168
Atopic dermatitis, toxigenic and nontoxigenic strains, in children, 1066
AZT (*See* Zidovudine)
Aztreonam, versus aminoglycoside therapy, nephrotoxicity and ototoxicity, 683

Bacillus anthracis, detection of spores by PCR, 1145
Bacteremia due to
  encapsulated bacteria, C4B deficiency, 942
  H. influenzae, in adults, S42
  M. avium–M. intracellulare complex, in HIV infection, 1082
Bacterial polysaccharide immune globulin, for *H. influenzae* type b and pneumococcal infections, S129
Bacteriolysis, of *E. coli*, by neonatal serum, 290
Bacteriuria, due to resident colonic *E. coli*, 46

Bacteroides species, scalp infection, after owl attack, 975
Baicalin, for HTLV-I infection, 433
Bartonella bacilliformis, interaction with endothelial cells, 1138
β-lactam antibiotics, effect on in vitro induction of LPS, 1033
B lymphocyte, activation by pneumoccocal polysaccharides, S71
Bone marrow
  progenitor cell differentiation, in vitro suppression by HHV-6, 925
  transplant recipients
    amphotericin B prophylaxis, 891
    IVIG prophylaxis for CMV, 972
Borrelia burgdorferi
  antibody, prevalence, 1133
  antigens, effect on murine lymphocytes, 471
  cross-reactive antigenic determinants, 658
  cultivation from blood and lesion in panniculitis, 596
  European reservoir host for, 479
Brazilian purpuric fever, due to *H. influenzae* biogroup aegyptius, S16, S111
Breast milk
  rotavirus-specific antibody, effect on seroconversion, 826
  S. agalactiae transmission to neonates, 569
Burnout, among ID physicians, 224
BV-araU, for simian varicella virus infection, in monkey, 727

C5a-ase, on group B streptococcus, antibody to, 315
C4B deficiency, in bacteremia or meningitis due to encapsulated bacteria, 942
Campylobacter jejuni
  associated with Guillain-Barré syndrome, serotype, 183
  quinolone resistance, 667
Campylobacter species
  diarrhea
    ciprofloxacin and loperamide for, 557
    travelers', 385
Cancer, IFN-αn3 for, 757
Candidiasis
  disseminated, due to amphotericin B–resistant *C. albicans*, 761
  esophageal, prevalence in Danish population, 389
Capsule, *H. influenzae* type b
  cap locus, for chromosomal encapsulation, S93
  genes, amplification status, S114
  influence on interactions with human endothelial cells, S115
Catheter, urinary, silver sulfadiazine to prevent bacteriuria, 14
CD4
  CD8 lymphocytes, levels in HIV infection, 427
  lymphocyte, circadian rhythms of counts, and cortisol levels, in HIV infection, 185
  naturally occurring soluble form, in HIV infection, 799
Ceftazidime, for *P. aeruginosa* and *S. epidermidis*, in vitro model, 281
Ceftriaxone, and penicillin G, for experimental neurosyphilis, 396
Central nervous system, infection by *H. influenzae* type b, molecular basis, S77
Cerebral malaria
  dietary fish-oil supplementation, 898
  smear-negative, mefloquine-resistant, 599
Cerebral toxoplasmosis, in AIDS, diagnosis by PCR, 982
Chagas' disease, due to *T. cruzi*, antibody detection by EIA, 585
Chancroid, TMP-SMZ versus fleroxacin for, 949
Chlamydia pneumoniae, infection, no association with chronic fatigue syndrome, 184
Chlamydia psittaci, intracellular antimicrobial activity against, 513
Chlamydia trachomatis
  asymptomatic carriage in men, urinary test for, 573
  ectopic pregnancy association, serologic and histologic correlates, 1076
Chloroquine, versus norfloxacin, for falciparum malaria, 904
Cholera, oral vaccine regimens, safety and efficacy, 1042
Chorioamnionitis
  circadian factors and infection, 393
  due to *H. influenzae*, in adults, S42
  preterm, IL-8 in cord serum as marker for, 957
Chronic fatigue syndrome, lymphokines and soluble cellular receptors, 994
Ciprofloxacin
  and loperamide, for traveler's diarrhea, 557
  for pneumonia, 775
Clarithromycin-minocycline, for murine toxoplasmosis, 788
Coccidioidomycosis, human immunity in, assessment of, 710
Complement, role in host defense against *H. influenzae*, S62, S75
Condyloma acuminata, IFN-αn3 for, 757
Coronavirus, rabbit, cause of myocarditis and congestive heart failure, 134
C-reactive protein, relationship to IL-6, in neutropenia, 886
Creuzfeldt-Jacob disease, amphotericin B for, failure, 784
Cryoglobulinemia, related to HCV infection, IFN-α2b for, 778
Cryptococcosis, in AIDS, liposomal amphotericin B for, 593
Cryptococcus neoformans, meningitis, in AIDS and neoplastic disease, 960
Cryptococcus neoformans–tetanus toxoid conjugate vaccine, antibody specificity, 1086
Cryptosporidium parvum
  development in chick embryo, 789
  infection
    experimental, in aged hamsters, 769
    paromomycin for, 772
Cutaneous infection, due to *Y. enterocolitica*, characteristics, 740
Cytokine
  induction by mycobacteria, 702
  in leishmaniasis, role in pathogenesis, 344
  secretion in endotoxin tolerance, 859
Cytomegalovirus
  glycoprotein B and neutralizing antibody responses, 381
  infection
    in HIV-related atypical pneumonia, 93
    IVIG prophylaxis in bone marrow transplant recipients, 972
  in lung transplantation, prophylaxis with ganciclovir, 548
  interaction with *P. carinii*, in HIV-related atypical pneumonia, 93

Dehydroepiandrosterone, as predictor for progression to AIDS, 413
Dermal hypersensitivity, in human coccidioidomycosis, 710
Dermatitis, atopic, toxigenic and nontoxigenic strains in children, 1064
Dexamethasone, lack of effect on encephalitis due to JEV, 631
Diarrhea
  due to
    E. coli, pediatric, 141, 144
    rotavirus
      human, prevention by bovine antibody, 623
      seroepidemiologic evaluation, 161
    Trichinella species, 908
  travelers', seasonal variation, 385
2',3'-dideoxyinosine, pharmacology in children, 99
Diphtheria and tetanus toxoids and pertussis vaccine, risk of poliomyelitis during outbreak, 444
Dirofilaria immitis, cause of small calcified nodule, 398
DNA, HTLV-I/II, PCR for, in blood donor screening, 369
DTP, injection, risk of poliomyelitis during outbreak, 444

Ectopic pregnancy, association with *C. trachomatis*, 1076
Edward H. Kass Memorial Lecture, epidemiologic classics, 235
EIA, to detect antibody to *T. cruzi*, 585
ELISA, to detect
  IgM antibody to type III GBS, 1049
  p24 antigen, acid dissociation, 913
  sCD4 complexed with gp120 HIV envelope protein, 799
Encephalitis, due to
  JEV, dexamethasone for, 631
  T. gondii, diagnosis by PCR, 982
Endocarditis, due to *S. aureus*, effect of microcapsule expression on virulence, 749
Endothelial cell
  activation by *T. pallidum*, 484
  injury, bacteria-mediated, 651
Endotoxin
  effect on serum granulocyte and GM-CSF levels, in dogs, 689
  shock, due to *N. meningitidis*, limulus anti-LPS for, 494
  tolerance, altered cytokine secretion, 859
Epidemiology
  AIDS, global perspective, IDSA meeting presentation, 245
  B. burgdorferi, antibody prevalence, 1133
  burnout among ID physicians, 224
  C. albicans, esophageal, prevalence in Danish population, 389
  diarrhea
    pediatric, due to
      E. coli, 144
      Shigella species, 144
    travelers', seasonal variation, 385
  Edward H. Kass Memorial Lecture, epidemiologic classics, 235
  hepatitis A outbreak, 613
  hepatitis C virus, mother-to-child transmission detected by PCR, 720
  hepatitis E, acute sporadic, in Sudanese children, 1001
  H. influenzae
    disease, S2, S7, S11, S16, S20, S26, S29, S33, S34, S36, S38, S42
    incidence and clinical characteristics, S42
    nasopharyngeal carriage, S38
    type b
      invasive disease, S2, S7, S11
      respiratory tract infections, in children, S20, S26
  HIV
    heterosexual transmission, 541
    and HSV, heterosexual transmission, 251
    prevalence among patients with tuberculosis, 87
    in STD patients, 541
  HIV-1
    geographic diversity, 256
    risk among infants of HIV-seropositive mothers, 262
  HSV, infection, as risk factor for HIV, in heterosexuals, 251
  HTLV-I and -II infection, in STD patients, 920
  ID physicians, 205
  IDSA
    burnout among physicians, 224
    practice patterns, 218
  influenza epidemic, pediatric hospitalization in Japan, 373
  legionnaires' disease, outbreak associated with grocery store mist machine, 736
  L. pneumophila, contamination of hospital water distribution systems, 565
  M. avium complex, 577
  measles
    impact of vaccination program in Hong Kong, 1111
    risk among infants of HIV-seropositive mothers, 262
  meningococcal meningitis, epidemics, clonal analysis, 53
  poliomyelitis, risk after DTP injection, during outbreak, 444
  rotavirus, diarrhea, seroepidemiologic evaluation, 161
  RSV, outbreak in bone marrow transplant center, 987
  S. agalactiae, transmission in breast milk to neonates, 569
  S. pyogenes, vertical transmission and cross-colonization, 147
  trichinosis outbreak in Arctic, 908
  viral hepatitis, among US Navy ship personnel, 716
Epstein-Barr virus, infection, lymphokines and soluble cellular receptors, 994
Escherichia coli
  bacteriolysis of, by neonatal serum, 290
  diarrhea, pediatric, 141, 144
  effect of nonoxynol-9 on, 19
  enteroaggregative, drug resistance and intestinal adherence, 744
  ETEC, travelers' diarrhea, 385
  O111:B4, LPS, MAbs to, 34
  resident colonic strains, uropathogenic characteristics, 46
  resistance, to serum bactericidal activity, 953
  Shiga-like toxin–producing, virulence factors, 979
Esophageal disorders, due to *C. albicans*, in Danish population, 389

Falciparum malaria, chloroquine versus norfloxacin for, 904
Filariasis
  IgG4 after diethylcarbamazine and ivermectin treatment, 1158
  due to *O. volvulus*, strain-related pathogenicity, 964
Fimbriae, *H. influenzae*, mediation of adherence, S97
Fish oil, dietary, use in gram-negative infection and in cerebral malaria, in mouse, 898
Flavonoid compound, for HTLV-I infection, 433
Fleroxacin, versus TMP-SMZ, for chancroid, 949
Flucloxacillin, for *P. aeruginosa* and *S. epidermidis*, in vitro model, 281
Fluconazole, for cryptococcal meningitis, in HIV infection, 787
Fungal infection, due to *N. transvalensis*, in immunocompromised patients, 175
Fusarium solani, amphotericin B for, 1155

γ δ T lymphocytes, in
  HIV-1 infection, subset increase, 917
  tuberculous infection, response, 507
Ganciclovir, for CMV in lung transplant recipients, failure, 548
Giardia lamblia, infection, mebendazole versus metronidazole for, 1171
Glucocorticoids, systemic, for selected infections, 1
Glycolipid A, MAbs to, complement species-specific effector functions, 26
Glycoprotein, of *P. carinii*, antigenic variation, 329
Glycoprotein 120, and sCD4 complexes, in HIV infection, 799
Gram-negative infection, dietary fish-oil supplementation, 898
Gram-positive infection, in neutropenic cancer patients, 591
Granulocyte colony-stimulating factor, effects of endotoxin on, dog model, 689
Granulocyte-macrophage colony-stimulating factor
  effects of endotoxin on, dog model, 689
  recombinant human, for group B streptococcal neonatal sepsis, rat model, 938
Group B streptococcus
  antibody to C5a-ase, 315
  inactivation in the lung, 306
  sepsis, neonatal, GM-CSF for, 938
  type III, IgM antibody to, in infants, 1049
Guillain-Barré syndrome, due to *C. jejuni*, specific serotype, 183

Haemobartonella-like bacterial infection, ultrastructural pathology, in AIDS, 976

Haemocin, production by *H. influenzae*, S118
Haemophilus ducreyi, pili expression, S198
Haemophilus influenzae
ampicillin-resistant, non-β-lactamase-producing, S107
biogroup aegyptius
adherence and entry of epithelial cells, S111
Brazilian purpuric fever, S16
fimbria-mediated adherence and hemagglutination, S97
haemocin production, S118
hemagglutinating pili, S105
IgA1 proteases, S192
incidence and clinical characteristics, S42
infection, effect of pertussis toxin on susceptibility, infant rat model, 945
interactions with human endothelial cells, in vitro, S115
invasive disease, pathogenesis, S77, S82, S86, S90, S93, S97, S100, S103, S105, S106, S107, S109, S110, S111, S114, S115, S117, S118, S119
LPS, cytotoxic effect on bovine brain endothelial cells, in vitro, 865
multiresistant strains, molecular epidemiology, 1069
nasopharyngeal carriage, pediatric, S38
nonencapsulated
epidemiology and prevention, S177
in pediatric pneumonia, S205
noninvasive disease, animal models for pulmonary clearance, S185
nontypeable
acute bronchitis, S194
analysis of pilin-like gene, S201
interaction with respiratory mucosa, S100
intestinal immunization for respiratory immunity, S199
OMP and LPS, S181
otitis media, chinchilla model, S196
non-type b
outer membrane subtypes, S33
role of capsular polysaccharide serotype, population-based study, S34
P2 outer membrane protein, S181, S203
P6 outer membrane protein, S203
receptors for human transferrin, S103
type b
adherence
effect of pili-specific antibodies, 464
and entry, effect of capsule loss, S117
α-pilins, S106
amplification status of capsule genes, S114
antibody to PRP, 753
capsular saccharides, immunogenicity in infants, S160
complement, role in host defense, S62, S70, S74
disease, bacterial polysaccharide immune globulin for treatment or prevention, S129
encapsulation genetics, S93
immune response to
capsular polysaccharide, ontogeny, S57
polysaccharide, S44, S49, S53, S57
immunity and immunoglobulin allotype, S66
invasive disease
epidemiology S2, S7, S11
molecular basis, S77
lipooligosaccharide synthesis genes, S195
maternal immunization with capsular polysaccharide vaccine, S134
meningitis
blood-brain barrier changes, S119
incidence, S29
pathogenesis, S82
serum C-reactive protein, S36
nasopharyngeal infection, pathogenesis, S109
noncapsular surface antigens, S162
oligosaccharide conjugate vaccine, in infants, S139
outer membrane proteins P1 and P2, epitopes, S86
phase-variable lipopolysaccharide biosynthesis, S90
polysaccharide
antibody response in vitro, S161
immune response to, S44, S49, S53, S57, S62, S66, S70, S71, S74, S75
polysaccharide-protein conjugate vaccine, immunogenicity, S156
recombinant porin, S188
resistance, cell surface changes, S110
respiratory tract infections, in children, S20, S26
vaccine
biology of failure, S121
capsular polysaccharide or conjugate, S165
efficacy in Apache and Navajo children, S144
Finnish efficacy trials, S137
synthetic oligosaccharide, S152
untypeable, role of complement in host defense, S75
Heat shock proteins, of *B. burgdorferi*, 658
Helicobacter pylori, drug resistance, 974
Hemorrhagic fever with renal syndrome, nephropathia epidemica, detection of Puumala virus RNA, 934
Hepatitis A
antibodies to nonstructural protein, 273
outbreak associated with swimming pool, 613
Hepatitis B
IL-2 failure to augment humoral response, 775
vaccine failure, cause, 777
Hepatitis B virus infection
chronic, spontaneous HBsAg clearance, 831
precore sequence variations, in Chinese isolates, 127
production in U-937 cells, 929
second-generation HCV confirmatory test, 180, 181
surface antigen, spontaneous clearance during chronic infection, 831
Hepatitis C
chronic, in HIV-positive patients, recombinant IFN-α for, 723
cryoglobulinemia related to, IFN-α2b effect on, 778
virus
antibody response, in chimpanzees, 1006
mother-to-child transmission, detected by PCR, 720
propagation in salivary glands, 973
reactivity to c33c antigen as marker, 595
RNA detection by PCR in 5′ noncoding region, 1166
role in HBsAg clearance, 831
second-generation confirmatory test for HBV, 180, 181
weak immunity in infection, 438
Hepatitis E
acute sporadic, in Sudanese children, 1001
in macaque and owl monkey, 835
Hepatitis
IFN for, 593
viral, risk among US Navy ship personnel, 716
Herpes simplex virus infection
neonatal and postpartum IFN-γ and lymphocyte production, 813
as risk factor for HIV, in heterosexuals, 251
Herpes zoster
dissemination in the immunocompromised host, antivirals for, 450
due to VZV, after BMT, 119
Histamine-releasing factor, role in virus-induced asthma, 589, 590

Human herpesvirus 6
in vitro suppression of bone marrow progenitor cell differentiation, 925
infection in children, seroepidemiology, 1164
Human immunodeficiency virus
association with proctitis, in homosexual men, 150
heterosexual transmission, 541
HSV as risk factor for, in heterosexuals, 251
infection
antibody response to pneumococcal vaccine, 553
association with *M. fermentans* infection, 581
atypical pneumonia in, 93
biologic false-positive reactions for syphilis and, 1124
CD4 lymphocyte count
and cortisol level, circadian rhythms, 185
as predictor of disease progression, 352
ddI pharmacology, in children, 99
dehydroepiandrosterone, as predictor for progression to AIDS, 413
hepatitis C in, recombinant IFN-α for, 723
incidence of MAC bacteremia, 1082
of macrophages, in vitro, 80
measles antibody in, 589
neopterin monitoring of zidovudine therapy, 783
p24 as marker of disease progression, increased sensitivity, 913
p24-rich plasma as passive immunotherapy, 364
P. carinii antibody, 1151
prevalence among patients with tuberculosis, 87
resistance to zidovudine in, 105
and soluble CD4, 799
virus culture and p24 antigenemia in, 419
zidovudine and IFN-α combination therapy for, 793
and mycobacteria, dual infection, 80
serologic reactivity, geographic diversity, 256
type 1
absence from sweat, by PCR, 155
antibody, quantitative analysis, 111
cell-mediated immune response, in seronegative homosexual men, 1012
DNA, detection by PCR, 779, 781
gp160 candidate vaccine, 545
infection
early detection in infants, 394
γ δ T lymphocytes, 917
risk among infants of HIV-seropositive mothers, 262
RNA, quantitation in plasma, by PCR, 1119
T cell subsets in women before and after pregnancy, 1116
viral phenotype and immune response in, 427
Human leukocyte antigen, tuberculosis, and *M. tuberculosis*–specific antibody, 598
Human papillomavirus type 11, antibody-mediated neutralization, in mouse, 376
Human T cell leukemia/lymphotropic virus
type I
inhibition by baicalin, 433
PCR amplification, for blood donor screening, 369
types I and II
infection
confirmation and differentiation, 268
in STD clinic patients, 920
specific antibody-dependent cellular cytotoxicity, 805
Humoral immune system, mucosal, S167

IgA1 proteases, *H. influenzae*, S192
IgG4, levels in filariasis, after drug treatment, 1158
IgM antibody to group B streptococcus type III, in infants, 1049
Iloprost, effect on TNF mRNA transcription, 501
Immune globulin, for RSV prophylaxis, 456
Immunization against
DPT, in infants, effect of maternal antibody, 977
H. influenzae type b
biology of failure, S121
capsular polysaccharide or conjugate vaccine, S165
in chronic bronchitis, S20
efficacy in Apache and Navajo children, S144
Finnish efficacy trials, S137
in infants, S139
maternal, with capsular polysaccharide vaccine, S134
and pneumococcal infections, bacterial polysaccharide immune globulin, S129
Streptococcus pneumoniae, B lymphocyte activation by, S71
Immunization, intestinal, to prevent *H. influenzae* bronchitis, S199
Immunoglobulin, intravenous, prophylaxis for CMV, in bone marrow transplant recipients, 972
Immunoprecipitation, nondenaturing conditions, HAV nonstructural proteins, 273
Infectious Diseases Society of America
Edward H. Kass Memorial Lecture, epidemiologic classics, 235
glucocorticoids, for selected infections, 1
manpower and training
description of ID physicians, 205
editorial, 201
meeting presentation, global perspective of AIDS, 245
postdoctoral recruitment information, 189, 410
practice patterns, 218
preliminary program, 985
Presidential Address, 29th annual meeting, 229
Infectious diseases specialist, role in AIDS-related clinical research, 592
Infectious purpura, due to *N. meningitidis* and *H. influenzae*, anti–*E. coli* J5 plasma for, 695
Influenza A and B vaccines, immunization of infants, 727
Influenza virus, cause of pediatric hospitalization, 373
Intercellular adhesion molecule-1, induction by *T. pallidum*, 484
Interferon-α
nonneutralizing antibodies, 593
recombinant, for chronic hepatitis C in HIV infection, 723
and zidovudine, combination therapy for advanced HIV infection, 793
Interferon-α2b, for cryoglobulinemia related to HCV infection, 778
Interferon-αn3, for condyloma acuminata, 757
Interferon-γ
effect on antibody response to *H. influenzae* type b polysaccharide, S161
in human coccidioidomycosis, 710
in neonates and parturient women, 813
in toxoplasmosis, 1170
Interleukin-1
induction by
mycobacteria, 702
streptococcal exotoxins, role in TSS, 879
levels in primary EBV infection and in chronic fatigue syndrome, 994
production, during and after therapy for leishmaniasis, 1094
Interleukin-2, in human coccidioidomycosis, 710
Interleukin-4, in leishmaniasis, role in pathogenesis, 344
Interleukin-6
effect on antibody response to *H. influenzae* type b polysaccharide, S161
induction by mycobacteria, 702

relationship to C-reactive protein and fever, in febrile neutropenia, 886
Interleukin-8, in cord serum, marker for detection of preterm chorioamnionitis, 957
Intravenous immunoglobulin, prophylaxis for CMV, in bone marrow transplant recipients, 972
Iron acquisition, transferrin receptors on *H. influenzae*, S103

Japanese encephalitis virus, infection, dexamethasone for, 631

Ketoconazole
for cutaneous leishmaniasis, 528
inhibition of cholesterol synthesis, effect on amphotericin B, 337

Lactobacilli, H_2O_2 production, correlation with susceptibility to spermicide, 1142
Lactobacillus acidophilus, to control vaginal flora, 19
Legionnaires' disease
contamination of hospital water distribution systems, 565
outbreak associated with grocery store mist machine, 736
Leishmania braziliensis, cutaneous infection, natural history, 518
Leishmania donovani, intracellular antimicrobial activity against, 513
Leishmania donovani chagasi, infection, pediatric, immunologic markers of disease progression, 535
Leishmania mexicana, cutaneous infection, natural history, 518
Leishmaniasis, cutaneous
American, sodium stibogloconate for, 968
pathogenesis, role of IL-4, 344
sodium stibogluconate for, 528
visceral, IL-1 and TNFα production during and after therapy, 1094
Limulus anti-LPS factor, treatment of endotoxin shock, 494
Lipooligosaccharide synthesis genes, *H. influenzae* type b, S195
Lipopolysaccharide
E. coli, composition, and resistance to bactericidal activity, 953
H. influenzae
cytotoxic effect on bovine brain endothelial cells, in vitro, 865
nontypeable, S181
type b, biosynthesis, S90
induction by β-lactam antibiotics, 1033
MAbs to, antibacterial and protective properties, 34
tolerance, altered cytokine secretion in, 859
Loperamide, and ciprofloxacin, for traveler's diarrhea, 557
Lyme disease
lymphocyte proliferation, nonspecific, mouse model, 471
serologic diagnosis using outer surface proteins and flagellin, 1127
spirochete, European reservoir host for, 479
Lymphocyte
activation by VZV, expression of IL-2 receptors, 158
CD4, for predicting disease progression in HIV infection, 352
production, in neonates and parturient women, 813
response to *B. burgdorferi* antigens, 471
sCD4 release, reflection of HIV disease progression, 799
transformation in human coccidioidomycosis, 710
Lymphokines, levels in primary EBV infection and in chronic fatigue syndrome, 994

Macrophage
HIV and mycobacterial infection of, 80
infection by RSV, 819
J774, antibiotic transport in, 322
killing of *T. pallidum*, 69
Malaria, cerebral, smear-negative, mefloquine-resistant, 599
Measles
risk, among infants of HIV-seropositive mothers, 262
vaccination program, impact on epidemiology, 1111
Mebendazole, for *G. lamblia* infection, versus metronidazole, 1171
Meningitis
blood-brain barrier changes, S119
due to
C. neoformans
in AIDS and neoplastic disease, 960
fluconazole as possible prophylaxis for, 787
encapsulated bacteria, no increase in C4B deficiency, 942
H. influenzae type b
incidence, S7, S29
pathogenesis, S77, S82
serum C-reactive protein, S36
N. meningitidis, epidemics, 53
Meningococcemia, anti–*E. coli* J5 plasma for, 695
Metronidazole, for *G. lamblia* infection, versus mebendazole, 1171
Microcapsule, of *S. aureus*, effect on virulence, 749
Monoclonal antibody to
glycolipid A, complement species-specific effector functions, 26
LPS
antibacterial and protective properties, 34
inhibition of production by TNF, 873
M. catarrhalis
nasopharyngeal carriage, infant, S38
pulmonary clearance, mouse model, 644
mRNA, of HPV-11, as primary marker of viral infection, 376
Mumps, association with vaccine and parotitis, 186
Mycobacterium avium, resistance in HIV infection, 179
Mycobacterium avium–M. intracellulare complex
bacteremia, in HIV infection, 1082
cytokine induction by, 702
infection
disseminated
association with HIV infection, 577
from intestinal tract, animal model, 75
of macrophages in vitro, 80
Mycobacterium tuberculosis
infection of macrophages, in vitro, 80
response of $\gamma\,\delta$ T lymphocytes, 506
Mycoplasma fermentans, association with HIV infection, 581
Myocarditis, due to rabbit coronavirus infection, 134

Nasopharyngeal infection, due to *H. influenzae* type b, pathogenesis, S109
Neisseria gonorrhoeae, asymptomatic carriage in men, urinary test for, 573
Neisseria meningitidis
endotoxin shock, limulus anti-LPS for, 494
serogroup A, clonal analysis, 53
Neoplastic disease, *C. neoformans* meningitis in, outcome, 960
Neopterin, for zidovudine monitoring in HIV infection, 783
Nephropathia epidemica, detection by nested primer-based PCR, 25
Nephrotoxicity
due to amphotericin B, role of cholesterol, 337
and ototoxicity, in aminoglycoside versus aztreonam therapy, 683
Neurosyphilis, experimental, penicillin G and ceftriaxone for, 396
Neutralization of
HCMV, by antibodies to glycoprotein B, 381
HPV-11 particles, 376
Neutropenia, febrile, IL-6 and C-reactive protein, for assessment, 886
Nocardia transvalensis, disseminated infection, in immunocompromised patients, 175

Nonoxynol-9, effect on
H_2O_2 production by lactobacilli, 1142
vaginal flora, 19
Norfloxacin, versus chloroquine, for falciparum malaria, 904

Onchocerca volvulus
infection, cellular and immune responses, 1163
strain-related pathogenicity, 964
Organic anion transporters, antibiotic transport by, 322
Otitis media
bacterial adherence, 1150
due to *H. influenzae*, nontypeable, chinchilla model, S196
Ototoxicity
aminoglycoside-induced, detection, 1026
and nephrotoxicity, in aminoglycoside versus aztreonam therapy, 683
Outer membrane protein, *H. influenzae*
nontypeable, S181
subtypes, S33
type b, epitopes, S86
Outer surface proteins A and B, serologic diagnosis in Lyme disease, 1127

p24 antigen
detection, increased sensitivity by acid dissociation, in HIV infection, 913
marker for progression of HIV disease, 419
response to zidovudine and IFN-α combination therapy, for AIDS, 793
Panniculitis, due to *B. burgdorferi*, cultivation and PCR detection, 596
Papillomavirus, human genital infection, tampon method for assessment, 1103
Parainfluenza virus type 3, isolation from CSF, 1167
Paromomycin, for *C. parvum* infection, 772
Parotitis, after vaccination against mumps, 186
Pasteurella haemolytica, endothelial cell injury by, 651
Pediatric infectious diseases postdoctoral training programs, 601
Penicillin
and ceftriaxone, for experimental neurosyphilis, 396
cellular transport, 322
resistance among type 9L pneumococci, 671
Pentostam, for cutaneous leishmaniasis, 528, 968
Pertussis toxin, effect on susceptibility to *H. influenzae*, infant rat model, 945
Phagocyte
endothelial cell interaction, 651
reactive nitrogen intermediates, role in activity, 513
Pharmacology, ddI in children, 99
Pili
H. ducreyi, expression, S198
H. influenzae, hemagglutinating, S105
Pilin-like gene, *H. influenzae*, cloning and sequence analysis, S201
Pilins, *H. influenzae* type b, comparison, S106
Plasmid, enteroaggregative *E. coli*, for drug resistance and adherence, 744
Platelet-activating factor, role in virus-induced asthma, 589, 590
Pneumocystis carinii
antibody response in HIV infection, 1151
antigenic variation of gp120, 329
interaction with CMV, in HIV-related atypical pneumonia, 93
pneumonia, 8-aminoquinolones for, 764
Pneumonia
ciprofloxacin for, 775
due to
group B streptococcus, 306
H. influenzae, pediatric, nonencapsulated, S205
P. carinii, 8-aminoquinolones for, 764
Sendai virus, pulmonary histopathology in protein-deprived mouse, 846
Polymerase chain reaction
to detect
B. anthracis spores, 1145
HCV RNA, 438, 720, 1166
HIV-1 DNA, 779, 781, 1119
HTLV-I, in blood donors, 369
M. fermentans, 581
nephropathia epidemica virus RNA, 934
T. gondii DNA, 982
VZV DNA, 619
to quantify proviral HIV DNA, 793
Polysaccharide
pneumococcal, B lymphocyte activation by, S71
side chain length, in *E. coli*, determinant of resistance, 953
Porin, *H. influenzae* type b, recombinant, S188
P2, outer membrane protein of *H. influenzae*, S181, S203
P6, outer membrane protein of *H. influenzae*, S203
Pregnancy
ectopic, association with *C. trachomatis*, 1076
labor, preterm, circadian factors and infection, 393
T cell subsets during and after, in HIV-1–infected mothers, 1116
Presidential Address, IDSA, 29th annual meeting, 229
Probenecid, inhibition of antibiotic transport, 322
Proctitis, association with HIV, in homosexual men, 150
Prosthetic hip implants, pseudoinfection, 981
Pseudomonas aeruginosa, antibiotic treatment of suspended and adherent cells, 281
Pseudomonas pseudomallei, TNF and, 561
Pulmonary infection, due to *M. catarrhalis*, mouse model, 644
Pyelonephritis, histopathology, mouse model, 299

Quinolone
cellular transport, 322
resistance, in *C. jejuni*, 667

Resistance
E. coli, to serum bactericidal activity, 953
H. influenzae
non-β-lactamase-producing, to ampicillin, S107
type b, associated with cell surface changes, S110
HIV, to zidovudine, 105
M. avium, in HIV infection, 179
Respiratory syncytial virus
effect on immune response, 819
infection
in bone marrow transplant center, outbreak, 987
immune globulin, for prevention, 456
in pediatric liver transplant patients, 166
Respiratory tract infection, due to *H. influenzae*
bronchitis, S194
humoral immunity, S167
interaction with mucosa, S100
nonencapsulated, epidemiology and prevention, S177
type b, in children, S20, S26
Respiratory viruses, histamine-releasing factor, induced by, 589, 590
Restriction fragment length polymorphism analysis, of *S. pyogenes*, vertical transmission and cross-colonization, 147
River blindness, due to *O. volvulus*, strain-related pathogenicity, 964
Rotavirus
antibody in breast milk, effect on seroconversion, 826

diarrhea
bovine antibody prophylaxis, 623
seroepidemiologic evaluation, 161
T cell responses in children and adults, 1107

Salivary glands, propagation of HCV in, 973
Salmonella species, diarrhea, ciprofloxacin and loperamide for, 557
Sendai virus pneumonia, pulmonary histopathology in protein-deprived mouse, 846
Sepsis, neonatal, due to group B streptococci, rat model, 938
Septic shock, anti-*E. coli* J5 plasma as immunotherapy, 695
Septicemic melioidosis, TNF and, 561
Sexually transmitted disease
association with HIV infection, 541
asymptomatic *N. gonorrhoeae* and *C. trachomatis*, test for men, 573
clinics, HTLV-I and -II in patients, prevalence, 920
Shiga-like toxin production, *E. coli*, virulence, 979
Shigella species, diarrhea, pediatric, 144
Shigellosis, natural immunity, partial expression, 785
Silver sulfadiazine, to prevent catheter-associated bacteriuria, 14
Simian immunodeficiency virus, infection, and concurrent experimental syphilis, 1020
Simian varicella virus, infection, BV-araU for, monkey model, 727
Sodium stibogluconate, for cutaneous leishmaniasis, 528, 968
Spermicide, nonoxynol-9 effect on
H_2O_2 production by lactobacilli, 1142
vaginal flora, 19
Sputum, washing, for diagnosis of *S. pneumoniae* and other organisms, 397
Staphylococcus aureus
endocarditis, effect of microcapsule expression on virulence, 749
skin colonization, pediatric, 1064
toxins, in AIDS, 638
TSST-1, variant toxin sequencing, 1056
Staphylococcus epidermidis, antibiotic treatment of suspended and adherent cells, 281
Steroid therapy, IDSA guidelines for selected infections, 1
Streptococcal toxic shock syndrome, TNFα and IL-β1 synthesis, by stimulated monocytes, 879
Streptococci, group B, effect of capsule on clearance, 306
Streptococcus agalactiae, transmission in breast milk, 569
Streptococcus pneumoniae
capsular polysaccharide, antibody response in HIV infection, 553
nasopharyngeal carriage, in infants, S38
penicillin resistance, clonal origin, 671
pneumonia, washing of sputum for diagnosis, 397
Streptococcus pyogenes, vertical transmission and cross-colonization, 147
Streptolysin O, TNFα and IL-1β, induction in streptococcal TSS, 879
Stress, among ID physicians, 224
Syphilis
biologic false-positive reactions, 1124
and concurrent SIV infection, macaque model, 1020
killing of *T. pallidum* by macrophages, 69

T lymphocyte
$\gamma\ \delta$, increase in HIV-1 infection, 917
immunity
in infection due to VZV, 119
inhibition by RSV, 819
receptor, $\gamma\ \delta$, in HIV-1 infection, 917
response to
HIV-1, in seronegative homosexual men, 1012
rotavirus, in children and adults, 1107
subsets during and after pregnancy, in HIV-1–infected mothers, 1116
Tampon, method for assessment of human genital papillomavirus infection, 1103
Tetanus toxoid, antibody response, 977
Toxic shock syndrome
in AIDS, 638
due to *S. aureus*, sequencing of variant toxins, 1056
Toxoplasma gondii
DNA in CSF, detection by PCR, 982
intracellular antimicrobial activity against, 513
Toxoplasmosis
in AIDS, diagnosis by PCR, 982
clarithromycin-minocycline for, mouse model, 788
IFN-γ in immunocompromised patients, 1170
Transferrin, human, receptors on *H. influenzae*, S103
Traveler's diarrhea, ciprofloxacin and loperamide for, 557
Treponema pallidum
endothelial cell activation, 484
infection, in CNS, 396
killing by macrophages, 69
Trichinosis, epidemiologic and serologic definition, in Arctic, 908
Trimethoprim-sulfamethoxazole, versus fleroxacin, for chancroid, 949
Trypanosoma cruzi, antibody to, detection by EIA, 585
Tuberculosis
and HIV infection, prevalence, 87
HLA, and specific antibody, 598
response of $\gamma\ \delta$ T lymphocytes, 506
Tumor necrosis factor
inhibition of production, by MAbs to LPS, 873
in septic shock, role of, 501
in septicemic melioidosis, 561
Tumor necrosis factor-α
production, during and after therapy for leishmaniasis, 1094
synthesis in streptococcal TSS by stimulated monocytes, 879

U-937 cells, transfected with HBV, 929
Urinary leukocyte esterase test, to detect asymptomatic carriage of *N. gonorrhoeae* and *C. trachomatis*, in men, 573
Urinary tract infection
catheter-associated, silver sulfadiazine prophylaxis, 14
due to *E. coli*, resident colonic, 46
histopathology, mouse model, 299

Vaccine
C. neoformans–tetanus toxoid conjugate antibody specificity, 1086
live influenza A and B virus, intranasal, 727
Ty21a-based typhoid-cholera hybrid, oral, 182
pneumococcal
antibody response in HIV infection, 553
B lymphocyte activation by, S71
Vaccine against
cholera, oral, various regimens, 1042
H. influenzae type b
biology of failure, S121
capsular polysaccharide
or conjugate, S165
for maternal immunization, S134
capsular saccharides, immunogenicity in infants, S160
in chronic bronchitis, oral, S20
efficacy in Apache and Navajo children, S144
Finnish efficacy trials, S137

invasive bacterial disease, polysaccharide-protein conjugate, S156
oligosaccharide conjugate, in infants, S139
and pneumococcal infections, bacterial polysaccharide immune globulin, S129
polysaccharide-protein conjugate, immunogenicity, S156
synthetic oligosaccharide, S152
HIV-1, gp160 candidate vaccine, 545
measles, impact on epidemiology of disease, 1111
mumps, and parotitis, 186
varicella, live attenuated, cytotoxic T lymphocyte response to, 852
Vancomycin, empiric use in febrile neutropenia, 591
Varicella-zoster virus
cytotoxic responses after vaccination, 852
DNA, in PBMC of elderly, 619
lymphocyte activation by, 158
viremia, subclinical, after BMT, 119
Verruca peruana, interaction of *B. bacilliformis* with endothelial cells, 1138
Vidarabine, versus acyclovir, for disseminated herpes zoster, 450
Virulence
H. influenzae type b, S2
Shiga-like toxin–producing *E. coli*, 979
Visceral leishmaniasis, in children, immunologic markers of disease progression, 535

Western blot, to detect hepatitis E, new, 1003

Yersinia enterocolitica, cutaneous infection characteristics, 740

Zidovudine
for HIV infection, monitoring by neopterin, 783
and IFN-α, combination therapy for advanced HIV infection, 793
resistance in HIV infection, 105